Who are the target beneficiaries of the Rare Disease Medicines Access Program (RDMAP)?

Initial target beneficiaries are children with Types 1 and 3 Gaucher Disease referred by the (Institute of Human Genetics) IHG who qualify based on a standard screening process. Patients shall undergo treatment and management and have their regular Enzyme Replacement Therapy infusion.